Cargando…
Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016912/ https://www.ncbi.nlm.nih.gov/pubmed/29940039 http://dx.doi.org/10.1371/journal.pone.0199926 |
| _version_ | 1783334630337806336 |
|---|---|
| author | Buti, María Manzano, María L. Morillas, Rosa M. García-Retortillo, Montserrat Martín, Leticia Prieto, Martín Gutiérrez, María L. Suárez, Emilio Rubio, Mariano Gómez López, Javier Castillo, Pilar Rodríguez, Manuel Zozaya, José M. Simón, Miguel A. Morano, Luis E. Calleja, José L. Yébenes, María Esteban, Rafael |
| author_facet | Buti, María Manzano, María L. Morillas, Rosa M. García-Retortillo, Montserrat Martín, Leticia Prieto, Martín Gutiérrez, María L. Suárez, Emilio Rubio, Mariano Gómez López, Javier Castillo, Pilar Rodríguez, Manuel Zozaya, José M. Simón, Miguel A. Morano, Luis E. Calleja, José L. Yébenes, María Esteban, Rafael |
| author_sort | Buti, María |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6016912 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-60169122018-07-07 Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study Buti, María Manzano, María L. Morillas, Rosa M. García-Retortillo, Montserrat Martín, Leticia Prieto, Martín Gutiérrez, María L. Suárez, Emilio Rubio, Mariano Gómez López, Javier Castillo, Pilar Rodríguez, Manuel Zozaya, José M. Simón, Miguel A. Morano, Luis E. Calleja, José L. Yébenes, María Esteban, Rafael PLoS One Correction Public Library of Science 2018-06-25 /pmc/articles/PMC6016912/ /pubmed/29940039 http://dx.doi.org/10.1371/journal.pone.0199926 Text en © 2018 Buti et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Buti, María Manzano, María L. Morillas, Rosa M. García-Retortillo, Montserrat Martín, Leticia Prieto, Martín Gutiérrez, María L. Suárez, Emilio Rubio, Mariano Gómez López, Javier Castillo, Pilar Rodríguez, Manuel Zozaya, José M. Simón, Miguel A. Morano, Luis E. Calleja, José L. Yébenes, María Esteban, Rafael Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study |
| title | Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study |
| title_full | Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study |
| title_fullStr | Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study |
| title_full_unstemmed | Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study |
| title_short | Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study |
| title_sort | correction: randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis b virus reactivation in anti-hbc-positive patients with rituximab-based regimens to treat hematologic malignancies: the preblin study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016912/ https://www.ncbi.nlm.nih.gov/pubmed/29940039 http://dx.doi.org/10.1371/journal.pone.0199926 |
| work_keys_str_mv | AT butimaria correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT manzanomarial correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT morillasrosam correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT garciaretortillomontserrat correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT martinleticia correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT prietomartin correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT gutierrezmarial correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT suarezemilio correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT rubiomarianogomez correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT lopezjavier correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT castillopilar correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT rodriguezmanuel correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT zozayajosem correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT simonmiguela correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT moranoluise correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT callejajosel correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT yebenesmaria correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy AT estebanrafael correctionrandomizedprospectivestudyevaluatingtenofovirdisoproxilfumarateprophylaxisagainsthepatitisbvirusreactivationinantihbcpositivepatientswithrituximabbasedregimenstotreathematologicmalignanciesthepreblinstudy |